While the predictive value of PD‐L1 in melanoma remains controversial, the U.S. Food and Drug Administration has updated the indications for PD‐1 inhibitors in the first‐line treatment of NSCLC, implying the importance of PD‐L1 as a biomarker (https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda-checkpoint-inhibitor). This evidence concerns the gene CD274 and non-small cell lung carcinoma.